(1) Atlas of chronic kidney disease in the United States. Incidence, prevalence, patient characteristics, & Modality. United State Renal Data System (USRDS). 2012 Annual data 215-228.
(3) El Minshawy O. End-stage renal disease in the El-Minia Governorate, upper Egypt: An epidemiological study. Saudi J Kidney Dis Transpl 2011;22:1048-54.
(4)Leung KCD. Psychosocial aspects in renal patients. Perit Dial Int. 2003; Suppl 2:S90-4.
(5) Robinson-Bostom L and DiGiovanna JJ. Cutaneous manifestations of end stage renal disease. J Am Acad Dermatol. 2000;43(6):975-86.
(6) Cordova KB, Oberg TJ, Malik M and Robinson-Bostom L. Dermatologic conditions seen in end-stage renal disease. Semin Dial. 2009;22(1):45-55
(7) Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW and Port FK. Pruritus in haemodialysis patients: International results from the
Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006; 21(12):3495-3505.
(8) Sultan M, Mansour H, Wahby I and Houdery A. Cutaneous manifestations in Egyptian patients with chronic renal failure on regular hemodialysis. J Egypt Women Dermatol Soc. 2010; 7 :49-55.
(9) Jovanović M. Current concepts of pathophysiology, epidemiology and classification of pruritus. Srp Arh Celok Lek. 2014;142(1-2): 106-112.
(10) Matsuda H, Coughlin MD, Bienenstock J and Denburg JA. Nerve growth factor promotes human hemopoieticcolony growth and differentia-tion.
Proc Natl Acad Sci U S A. 1988;85(17):6508-12.
(11) Aloe L, Bracci-Laudiero L, Bonini S and Manni L. The expanding role of NGF: from the neurotrophic activity to immunological diseases. Allergy, 1997;52(9):883-904.
12) Holzer P. Local effector function of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neurosci. 1988; 24, 739- 768.
13) Pincelli C and Marconi A. Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci. 2000;22(2): 71-79.